目的：探讨经前期综合征（PMS）肝气郁证模型大鼠海马脑区μ阿片受体（MOR）分布形态、蛋白水平表达，初步揭示PMS肝气郁证的发生机理及舒郁胶囊对该病证的干预作用。方法：采用慢性束缚应激法复制PMS肝气郁证模型大鼠，分别予以调肝方药舒郁胶囊进行干预。采用免疫荧光标记（IF）和蛋白免疫印迹（WB）技术对各组大鼠海马CA1、CA3脑区MOR进行检测。结果：与正常组大鼠相比，模型组大鼠海马脑区MOR分布排列杂乱且蛋白含量增多（P<0.01），给予药物干预后，MOR蛋白含量基本恢复至正常水平。结论：PMS肝气郁证的发病机理可能与大鼠海马中CA1、CA3区 MOR高表达有关；舒郁胶囊可以有效纠正其恢复近正常水平，这可能是舒郁胶囊治疗PMS肝气郁证的中枢机制之一。

This study was aimed to discuss the distribution and protein expression level of μ-opioid receptor (MOR) in hippocampus of premenstrual syndrome (PMS) liver-qi stagnation rat model, in order to initially reveal the action mechanism of PMS liver-qi stagnation and intervention effect of Shu-Yu (SY) capsule. Chronic restraint stress method was used to copy PMS liver-qi stagnation rat model. SY capsule of Tiao-Gan prescription was given as intervention. Immunofluorescence (IF) and western blot (WB) technique were used to detect MOR in hippocampal CA1 and CA3 brain area of rats from each group. The results showed that compared with the normal group, the hippocampus MOR distribution arrangement was messy with increased protein concentration in the model group (P < 0.01). After drug intervention, the MOR protein level returned to normal level. It was concluded that the pathogenesis of PMS liver-qi stagnation may be associated with high expression of MOR in hippocampus CA1 and CA3 region of rats. SY capsule can effectively correct and restore it to nearly normal level. It may be one of the central mechanisms in SY capsule treatment of PMS liver-qi stagnation.

国家自然科学基金委面上项目（81173162）：从BDNF/ERK信号途径探讨μ阿片受体在PMS肝气郁证中的作用机制，负责人：薛玲；国家自然科学基金委青年基金项目（81102537）：血管内皮生长因子（VEGF）在愤怒郁怒情绪反应中的作用机制，负责人：孙鹏。